Back HIV/AIDS HIV/AIDS Topics HIV Treatment IAS 2015: START Supports ART For All [VIDEO]

IAS 2015: START Supports ART For All [VIDEO]

alt

Full results from the Strategic Timing of Antiretroviral Treatment (START) trial provide definitive evidence that starting antiretroviral therapy (ART) soon after HIV diagnosis, rather than waiting until the CD4 T-cell count falls below 500 cells/mm3, significantly reduces the risk of AIDS-related and non-AIDS illness and death, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

[Jens Lundgren, IAS 2015, July 20, 2015]

Jens Lundgren from the University of Copenhagen gave an overview of the START findings at an IAS 2015 media briefing.

"There's been 20 years of controversy about whether to use ART in people with high CD4 counts," Lundgren said. "The data indicate that HIV treatment should be recommended for all HIV-positive people -- the challenge will be how to get the 22 million people not now on treatment onto treatment."

SEE ALSO: IAS 2015: START Trial Provides Definitive Evidence of Benefits of Early HIV Treatment

8/5/15

Reference

JD Lundgren. The Strategic Timing of Antiretroviral Treatment (START) Study: Results and their Implications. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Vancouver, July 19-22, 2015. Session MOSY03.